BioSante Pharmaceuticals to Present at the Susquehanna
Lincolnshire, Illinois (March 03, 2008) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its President and CEO, will present a corporate update and overview at the Susquehanna Financial Group’s Second Annual Healthcare Conference, at the W Hotel in New York City. Mr. Simes will present on Wednesday March 5, 2008 at 11:30 a.m. local time. The Susquehanna Conference will feature more than 50 companies presenting to institutional investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors.
A live audio webcast of BioSante’s presentation at the Susquehanna Conference may be accessed at biosantepharma.cdmail.biz/Webcasts.php and a replay will be available at the same link for 60 days.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver estradiol and testosterone. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™(estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Nycomed US, BioSante’s licensee.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.